Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - corifollitropin alfa 0.2 mg/ml;   - solution for injection - 100 mcg/0.5ml - active: corifollitropin alfa 0.2 mg/ml   excipient: hydrochloric acid methionine polysorbate 20 sodium citrate sodium hydroxide sucrose water for injection - controlled ovarian stimulation (cos) for the development of multiple follicles and pregnancy in women undergoing in-vitro fertilisation techniques.

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

organon (new zealand) limited - corifollitropin alfa 0.3 mg/ml;   - solution for injection - 150 mcg/0.5ml - active: corifollitropin alfa 0.3 mg/ml   excipient: hydrochloric acid methionine polysorbate 20 sodium citrate sodium hydroxide sucrose water for injection - controlled ovarian stimulation (cos) for the development of multiple follicles and pregnancy in women undergoing in-vitro fertilisation techniques.

Euroopa Liit - inglise - myHealthbox

finox biotech ag - follitropin alfa - solution for injection in pre-filled pen (injection). - 75 iu/0.125ml - anovulation - sex hormones and modulators of the genital systems - in adult women - anovulation (including polycystic ovarian disease, pcod) in women who have been unresponsive to treatment with clomiphene citrate. - stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (art) such as in vitro fertilisation (ivf), gamete intra-fallopian transfer (gift) and zygote intra-fallopian transfer (zift). - follitropin alfa in association with a luteinising hormone (lh) preparation is recommended for the stimulation of follicular development in women with severe lh and fsh deficiency. in clinical trials these patients were defined by an endogenous serum lh level < 1.2 iu/l. in adult men - follitropin alfa is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotrophic hypogonadism with concomitant human chorionic gonadotrophin (hcg) therapy.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - follitropin alfa, quantity: 625 iu/ml; lutropin alfa, quantity: 312.5 iu/ml - injection, solution - excipient ingredients: sucrose; poloxamer; methionine; phenol; arginine hydrochloride; dibasic sodium phosphate dihydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; phosphoric acid; water for injections - pergoveris is indicated for the stimulation of follicular development in women with severe lh and fsh deficiency.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - follitropin alfa, quantity: 625 iu/ml; lutropin alfa, quantity: 312.5 iu/ml - injection, solution - excipient ingredients: sucrose; poloxamer; methionine; phenol; arginine hydrochloride; dibasic sodium phosphate dihydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; phosphoric acid; water for injections - pergoveris is indicated for the stimulation of follicular development in women with severe lh and fsh deficiency.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - follitropin alfa, quantity: 625 iu/ml; lutropin alfa, quantity: 312.5 iu/ml - injection, solution - excipient ingredients: sucrose; poloxamer; methionine; phenol; arginine hydrochloride; dibasic sodium phosphate dihydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; phosphoric acid; water for injections - pergoveris is indicated for the stimulation of follicular development in women with severe lh and fsh deficiency.

Iisrael - inglise - Ministry of Health

organon pharma israel ltd., israel - corifollitropin alfa - solution for injection - corifollitropin alfa 100 mcg / 0.5 ml - corifollitropin alfa - corifollitropin alfa - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program.

Iisrael - inglise - Ministry of Health

organon pharma israel ltd., israel - corifollitropin alfa - solution for injection - corifollitropin alfa 150 mcg / 0.5 ml - corifollitropin alfa - corifollitropin alfa - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program.

Iisrael - inglise - Ministry of Health

organon pharma israel ltd., israel - follitropin beta - solution for injection - follitropin beta 833 iu / 1 ml - follitropin beta - follitropin beta - puregon is indicated for the treatment of female infertility in the following clinical situations: anovulation (including polycystic ovarian disease, pcod) in women who have beenunresponsive to treatment with clomiphene citrate. controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs [ e.g. in vitro fertilisation/embryo transfer (ivf/et), gamete intra-fallopian transfer (gift) and intracytoplasmic sperm injection (icsi)]. in the male : deficient spermatogenesis due to hypogonadotrophic hypogonadism.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - follitropin beta, quantity: 833 iu/ml - injection, solution - excipient ingredients: sucrose; sodium citrate dihydrate; polysorbate 20; benzyl alcohol; methionine; hydrochloric acid; sodium hydroxide; water for injections - female: anovulatory infertility and; controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. in vitro fertilisation and related procedures). male: for the treatment of deficient spermatogenesis due to hypogonadotrophic hypogonadism.